



Selinexor

Data Sheet

Catalog Number:	MC11061	Product Type:	Small Molecule
Bio-Activity:	Inhibitor of the nuclear export receptor CRM1/XPO1	CAS #:	1393477-72-9
Research Categories:	Neuroscience, cancer, inflammation	Chemical Name:	(Z)-3-[3-[3,5-Bis(trifluoromethyl)phenyl]-1,2,4-triazol-1-yl]-N'-pyrazin-2-ylprop-2-enehydrazide
Solubility:	Soluble in DMSO (up to at least 25 mg/ml) or in Ethanol (up to at least 25 mg/ml)	Molecular Formula:	C17H11F6N7O
Purity:	> 98%	Molecular Weight:	443.3
Format:	Powder	Ship Temp:	Ambient
Storage:	-20°C		

Application Notes

Description/Data:

Selinexor is a first-in-class chemotherapeutic, functioning by binding to Exportin-1 (XPO1, CRM1), a nuclear membrane-associated protein that aids transport of proteins into the cytoplasm [1,2]. It also helps maintain chromosome structure [3]. Inhibition of these functions in cancer cells results in sensitization to DNA damaging agents, cell cycle arrest, and apoptosis [4,5]. For example, it suppresses growth of T-cell acute lymphoblastic leukemia (T-ALL) cells (IC50 = 34-203 nM) [6]. and pancreatic cancer cells (IC50 ~ 150 nM) [7]. Currently in clinical trials for COVID-19 because of its ability to reduce inflammation [8].

References:

- 1) A Degterev et al. Nat. Chem. Biol. 2005 1:112
- 2) X Dong et al. Nature 2009 458:1136
- 3) Y Adachi & M Yanagida J. Cell Biol. 1989 108:1195
- 4) T Kashyap et al. Oncotarget 2018 9:30773
- 5) HY Fung & YM Chook Semin. Cancer Biol. 2018 9:30773

FOR RESEARCH USE ONLY

NEUROMICS' REAGENTS ARE FOR IN VITRO AND CERTAIN NON-HUMAN IN VIVO EXPERIMENTAL USE ONLY AND NOT INTENDED FOR USE IN ANY HUMAN CLINICAL INVESTIGATION, DIAGNOSIS, PROGNOSIS, OR TREATMENT. THE ABOVE ANALYSES ARE MERELY TYPICAL GUIDES. THEY ARE NOT TO BE CONSTRUED AS BEING SPECIFICATIONS. ALL OF THE ABOVE INFORMATION IS, TO THE BEST OF OUR KNOWLEDGE, TRUE AND ACCURATE. HOWEVER, SINCE THE CONDITIONS OF USE ARE BEYOND OUR CONTROL, ALL RECOMMENDATIONS OR SUGGESTIONS ARE MADE WITHOUT GUARANTEE, EXPRESS OR IMPLIED, ON OUR PART. WE DISCLAIM ALL LIABILITY IN CONNECTION WITH THE USE OF THE INFORMATION CONTAINED HEREIN OR OTHERWISE, AND ALL SUCH RISKS ARE ASSUMED BY THE USER. WE FURTHER EXPRESSLY DISCLAIM ALL WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE.-V2/08/2012

- 6) J Etchin et al. Br. J. Haematol. 2013 161:117
- 7) AS Azmi et al. Gastroenterology 2013 144:447
- 8) J Taylor et al. Lancet Haematol. 2020 7: e566

FOR RESEARCH USE ONLY

NEUROMICS' REAGENTS ARE FOR IN VITRO AND CERTAIN NON-HUMAN IN VIVO EXPERIMENTAL USE ONLY AND NOT INTENDED FOR USE IN ANY HUMAN CLINICAL INVESTIGATION, DIAGNOSIS, PROGNOSIS, OR TREATMENT. THE ABOVE ANALYSES ARE MERELY TYPICAL GUIDES. THEY ARE NOT TO BE CONSTRUED AS BEING SPECIFICATIONS. ALL OF THE ABOVE INFORMATION IS, TO THE BEST OF OUR KNOWLEDGE, TRUE AND ACCURATE. HOWEVER, SINCE THE CONDITIONS OF USE ARE BEYOND OUR CONTROL, ALL RECOMMENDATIONS OR SUGGESTIONS ARE MADE WITHOUT GUARANTEE, EXPRESS OR IMPLIED, ON OUR PART. WE DISCLAIM ALL LIABILITY IN CONNECTION WITH THE USE OF THE INFORMATION CONTAINED HEREIN OR OTHERWISE, AND ALL SUCH RISKS ARE ASSUMED BY THE USER. WE FURTHER EXPRESSLY DISCLAIM ALL WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE.-V2/08/2012

www.neuromics.com

Neuromics Antibodies • 5325 West 74th Street, Suite 8 • Edina, MN 55439
phone 866-350-1500 • fax 612-677-3976 • e-mail: pshuster@neuromics.com